C12N 2710/24011
Poxviridae
C12N2710/24011 (Poxviridae) appears on 1,175 US grants and 1,601 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,175
- Published applications
- 1,601
- Assignees
- 642
- Inventors
- 2,330
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 6 | 0 |
| 1992 | 12 | 0 |
| 1993 | 15 | 0 |
| 1994 | 13 | 0 |
| 1995 | 16 | 0 |
| 1996 | 11 | 0 |
| 1997 | 19 | 0 |
| 1998 | 42 | 0 |
| 1999 | 28 | 0 |
| 2000 | 24 | 0 |
| 2001 | 24 | 6 |
| 2002 | 22 | 22 |
| 2003 | 24 | 68 |
| 2004 | 26 | 53 |
| 2005 | 23 | 54 |
| 2006 | 35 | 65 |
| 2007 | 24 | 55 |
| 2008 | 26 | 62 |
| 2009 | 32 | 78 |
| 2010 | 39 | 78 |
| 2011 | 58 | 87 |
| 2012 | 46 | 76 |
| 2013 | 52 | 74 |
| 2014 | 49 | 45 |
| 2015 | 49 | 58 |
| 2016 | 34 | 57 |
| 2017 | 36 | 63 |
| 2018 | 54 | 60 |
| 2019 | 41 | 69 |
| 2020 | 50 | 85 |
| 2021 | 45 | 78 |
| 2022 | 41 | 84 |
| 2023 | 35 | 76 |
| 2024 | 37 | 62 |
| 2025 | 52 | 46 |
| 2026 | 26 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/24111OrthopoxvirusIndexing code978
- C12N 2710/24041Use of virus, viral particle or viral elements as a vectorIndexing code194
- C12N 2710/24022New viral proteins or individual genes, new structural or functional aspects ofIndexing code72
- C12N 2710/24034Use of virus or viral component as vaccineIndexing code49
- C12N 2710/24211ParapoxvirusIndexing code28
- C12N 2710/24032Use of virus as therapeutic agent, other than vaccineIndexing code23
- C12N 2710/24071Demonstrated in vivo effectIndexing code22
- C12N 2710/24021Viruses as suchIndexing code15
All 14 subgroupsShow fewer
- C12N 2710/24061Methods of inactivation or attenuationIndexing code9
- C12N 2710/24051Methods of production or purification of viral materialIndexing code8
- C12N 2710/24033Use of viral protein as therapeutic agent other than vaccineIndexing code7
- C12N 2710/24023Virus like particles [vlp]Indexing code1
- C12N 2710/24031Uses of virus other than therapeutic or vaccineIndexing code1
- C12N 2710/24088For redistributionIndexing code0
Recent patents
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- HIV immunotherapy with no pre-immunization step18 Aug 2026US 12,709,753 B2American Gene Technologies International Inc.
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2City of Hope
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Rapid selection system for the generation of recombinant enveloped viruses8 Oct 2026US 2026/0308627 A1Probiogen AG
- Antibody Specifically Binding to CD276, Preparation Method Therefor and Use Thereof1 Oct 2026US 2026/0297196 A1Shanghai Sinobay Biotechnology Co., Ltd.
- Coronavirus vaccines inducing broad immunity against variants24 Sep 2026US 2026/0284179 A1Cambridge Enterprise Limited
- Monobodies selective to nras10 Sep 2026US 2026/0263609 A1New York University
Most cited
By later US patents
- Modified vaccinia virus298US 4,603,112 AHealth Research, Inc. · 1986
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Vaccinia DNA172US 5,017,487 AHoffmann-La Roche Inc. · 1991
- Recombinant avipox virus and immunological use thereof151US 5,174,993 AHealth Research, Inc. · 1992
- Immunogenic composition comprising synthetically modified vaccinia virus144US 5,110,587 AHealth Research, Inc. · 1992